glp 1 long covid GLP-1 Treatments Show Promise for Symptoms GLP-1 receptor agonists in the

According to Leerink analyst David Reisinger, retatrutide showed higher gastrointestinal side effects than Zepbound, as expected, plus much higher rates of dysesthesia. William Blairs Andy Shea acknowledged that the placebo-adjusted weight loss compares favourably to the 18% figure for Zepbound but predicted the drug will likely be limited to individuals at the higher end of the BMI spectrum. In plain terms: retatrutide works spectacularly, but its probably too punishing for routine use

This side effect is common during most weight-loss interventions

it's a key player in appetite control, blood sugar balance and long-term metabolic health

Tell your prescriber if you notice changes